Dr Hermann Hauser, serial entrepreneur, co-founder of Amadeus Capital Partners and founder of semiconductor company, Arm Ltd, and gene-sequencing company, Solexa / Illumina, joins as chair of the ...

Synthego to develop multiplexed and complex genetic engineering strategies, increasing the safety and speed at which bit.bio can engineer human cells for cell therapies. bit.bio aims to leverage ...

A reliable supply of consistent and physiologically relevant motor neurons is fundamental to the study and screening of potential treatments for motor neuron diseases ioMotor Neurons also offer an ...

CAMBRIDGE, England, Dec. 2, 2025 /PRNewswire/ -- bit.b io, the global leader in cell programming technology, today announces the publication of its 2025 Corporate Sustainability Report, reaffirming ...

Automata, a leading robotics and automation company powering life sciences labs, today announced it is partnering with bit.bio, to automate a key aspect of the manufacturing process of their iPSC ...

BlueRock Therapeutics, a clinical-stage cell therapy company, and bit.bio, a synbio firm, signed a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T ...

Synthego, a provider of genome editing solutions, and bit.bio, a synthetic biology firm, said that they are expanding their strategic partnership to work on a platform for implementing synthetic ...

The Ginkgo Technology Network brings together over 25 diverse partners across an array of capabilities including AI, genetic medicines, biologics, and manufacturing. As a Ginkgo Technology Network ...

The report provides evidence-based metrics aligned with the UN Sustainable Development Goals (SDGs), highlighting year-over-year improvements. It demonstrates how sustainability is integrated across ...

Today bit.bio welcomed three new members to its Board of Directors, who bring their respective experience of turning world class science into new industries and company growth. The new directors will ...